A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies

This study is for adult patients (18 years and older) with B-cell non-Hodgkin lymphoma (B-NHL) who have already tried other treatments for their cancer. Because there are different types of B-NHL, the study looks at specific groups. For example, if you have Follicular Lymphoma (grades 1-3a), your cancer needs to have come back or not responded well after at least two other types of treatment.

Similar rules apply for other types of B-NHL, such as Diffuse Large B-cell Lymphoma (DLBCL) or Marginal Zone Lymphoma (MZL) – you would need to have tried at least two previous treatments. If you have Mantle Cell Lymphoma (MCL), you'll need to have tried at least one treatment, including a special type of medicine called a BTK inhibitor.

To join, doctors also need to see clear signs of the disease on scans like CT or MRI. You'll also need to be generally well, able to carry out your daily activities, and your body's organs, like your bone marrow, liver, and kidneys, must be working well. People with lymphoma affecting the brain or spinal cord, or suspected to be there, may not be able to join.

Taking part in this study would involve regular visits to the clinic to receive the study medicine, odronextamab. The specific schedule for these visits and how the medicine is given (for example, by injection or drip) would be explained in full detail by the study team. During these visits, you'd have various assessments, including blood tests to check how the medicine is affecting you and to measure the amount of odronextamab in your blood. You would also have scans, like CT or MRI, to see how the cancer is responding to the treatment. The study team would explain the exact number of visits, tests, and the total length of your participation, including any follow-up appointments after you stop taking the medicine.